Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tryptamine Therapeutics ( (AU:ENP) ) has shared an announcement.
Entropy Neurodynamics has reported successful dosing of the third patient in its clinical trial of TRP-8803, an IV-infused psilocin therapy for Binge Eating Disorder, with a full and controlled psychedelic response achieved. The company is close to completing dosing of the six-patient first cohort, has already enrolled four patients into the second cohort and is seeing early, clinically meaningful improvements in binge eating, mood and wellbeing, bolstering confidence in TRP-8803’s potential and reinforcing its positioning as a differentiated, scalable alternative to oral psilocybin in the emerging psychedelic-therapeutics market.
More about Tryptamine Therapeutics
Entropy Neurodynamics Limited is a Melbourne-based, clinical-stage biotechnology company focused on developing psychedelic-assisted therapies. Its lead candidate, TRP-8803, is an intravenously infused psilocin formulation designed to provide precise, controlled and reproducible psychedelic experiences, targeting Binge Eating Disorder and other neuropsychiatric conditions.
Average Trading Volume: 2,377,684
Technical Sentiment Signal: Sell
Current Market Cap: A$48.52M
Find detailed analytics on ENP stock on TipRanks’ Stock Analysis page.